You have started a new antiviral against covid-19, in the phase of the testes clinicians, reduziu pela metade or risco de internationale, segundo um estudo publicado nesta quarta-feira.
It is true that in recent years most recent developments have been critical, especially against new variants, such as Jeffrey Glenn, Stanford University immunology professor and co-author of this study, who published the revista “NEJM”.
Cerca de 500 pessoas ainda morrem diariamente por causa da doença nos Estados Unidos. In the United States, interferons, proteins released from released viruses and containing certain cell receptors, have become “a mecanismo defesa antivirale inato” (various antivirals) in recent years, Glenn explains.
There are different classes of interferons, entre eles os chamados lambdas. A peculiarity of the mesmos is that the main reasons for the pulmões of the covid-19s.
Whether it’s a completely new version of the interferon lambda, or to oversee the corona crisis, or to do a test for an ensaio clinic with more than 1,900 adults doing tinham, between June and fever of 2021 2022, no Brazil and Canada, with 85% dos pacientes já vacinados.
There were 931 pessoas received or treated, 25 foram hospitalizadas, versus 57 dos 1,018 pacientes who received placebo, or representing a difference of 51%, segundo or estudo. The results are so good that there are no vacancies.
“É spetacular”, explains Glenn, fundador da Empresa Eiger Biopharmaceuticals, who has developed into a trading partner and a good acionista.
Whether for the injection, or erece vantagem prática em relação ao antiviral Paxlovid, da Pfizer, ask for these comprimidos en serem tomados ao longo de cinco dias, argumentou or cientista.
Certos tratamentos, como os anticorpos monoclonais, assim como vacinas, aos poucos perderam sua eficácia frente às novas variantes. Anyway, there are different types of interferons connecting interferons, and there is no evolution of the virus.
Segundo of Eiger Biopharmaceuticals, which published previamente has imprensa results, an agência reguladora de medicamentos dos Estados Unidos (FDA) has not responded to an emergency authorization app. Mas Glenn is otimista: “Tenho esperança de que este estudo ajude a motivar os reguladores, aqui e em todo o mundo, a contrar uma forma de levar o tratamento aos pacientes o quanto antes.”
la/led/cjc/atm/lb